publications AR882, a potent and selective URAT1 inhibitor with a favorable pharmacological, pharmacokinetic and toxicity profile. ACR 2019 AR882, a potent and selective uric acid lowering agent acting through inhibition of uric acid reuptake, shows excellent pharmacokinetics and pharmacodynamics in a phase 1 clinical trial. ACR 2019 AR882, a potent and selective uricosuric agent, significantly reduced serum urate levels following multiple ascending once-daily doses in healthy subject volunteers. ACR 2020 AR882, a potent and selective uricosuric agent, significantly reduced serum urate in patients with gout in a phase 2a study. ACR 2020 Pharmacokinetics and serum urate lowering effects of AR882, a novel, potent and selective uricosuric agent, in patients with gout. EULAR 2021 Combination treatment of AR882, a new URAT1 inhibitor, and xanthine oxidase inhibitors allopurinol or febuxostat: effect on uric acid, hypoxanthine and xanthine in plasma or serum and urine. EULAR 2021 AR882, a potent and selective uricosuric agent, showed effectiveness in patients with various degrees of renal impairment. ACR 2021 AR882, a novel uricosuric agent, exhibited favorable pharmacokinetic profile and balanced excretion and metabolic pathways in a human AME study. ACR 2021
